Want to join the conversation?
$BIIB said the Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for marketing authorization of FLIXABI (infliximab). Previously known as SB2, FLIXABI is infliximab biosimilar candidate referencing Remicade, which was developed by Samsung Bioepis, the JV between Samsung BioLogics and $BIIB.
The latest earnings report by $VZ shows how it is losing customers despite offering the unlimited data plans, a record for the company.
$BEBE is closing down all its stores by the end of May.
$WFC agreed to hike its payout in a class-action settlement over unauthorized accounts by $32 million to $142 million for its retail sales practices. The settlement will now include customers who were impacted as early as May 2002.